The release of prostaglandin E2 inhibits the immunostimulatory effects of DAMPs, and prostaglandin E2 blockade activates DCs, followed by the priming of antitumor immune responses by CD8+ T cells, leading to tumor rejection and the failure to induce ICD [105]. The gene discussed is CD8A; the disease is neoplasm.